Oncternal Reports Second Quarter 2019 Financial Results and Provides Business Update
August 08, 2019 16:01 ET
|
Oncternal Therapeutics
SAN DIEGO, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Interim objective response rate of 100% in evaluable patients with CLL receiving the recommended dosing regimen of cirmtuzumab + ibrutinib supports...
Oncternal Therapeutics Announces Opening of Randomized Phase 2 Study of Cirmtuzumab in Combination with Ibrutinib
August 06, 2019 08:00 ET
|
Oncternal Therapeutics
SAN DIEGO, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc., (Nasdaq: ONCT) a clinical-stage biotechnology company developing potential first-in-class product candidates for cancers...
Oncternal Therapeutics to Report Second Quarter 2019 Financial Results and Provide Business Update
August 01, 2019 16:01 ET
|
Oncternal Therapeutics
SAN DIEGO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biotechnology company developing potential first-in-class product candidates for cancers...
Oncternal Therapeutics Completes Reverse Merger with GTx, Inc.
June 10, 2019 08:00 ET
|
Oncternal Therapeutics
SAN DIEGO, June 10, 2019 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc., (Nasdaq: ONCT) a clinical-stage biotechnology company developing potential first-in-class product candidates for cancers...
Oncternal Therapeutics Announces Updated Interim Data from a Phase 1/2 Study of Cirmtuzumab in Combination with Ibrutinib
June 03, 2019 16:00 ET
|
Oncternal Therapeutics
SAN DIEGO, June 03, 2019 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc., a clinical-stage biotechnology company focused on developing potential first-in-class product candidates for cancers with...
Oncternal Therapeutics to Present Interim Data from a Phase 1/2 Study of Cirmtuzumab in Combination with Ibrutinib at the 2019 American Society of Clinical Oncology Annual Meeting
May 15, 2019 17:01 ET
|
Oncternal Therapeutics
SAN DIEGO, May 15, 2019 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc., a clinical-stage biotechnology company focused on developing potential first-in-class therapeutic candidates for cancers...